J.P. Morgan analyst Cory Kasimov maintained a Buy rating on ACADIA Pharmaceuticals Inc (ACAD) yesterday. The company’s shares closed yesterday at $19.74.
According to TipRanks.com, Kasimov is a 2-star analyst with an average return of -0.2% and a 38.7% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Allogene Therapeutics Inc, Global Blood Therapeutics, and Jounce Therapeutics Inc.
Currently, the analyst consensus on ACADIA Pharmaceuticals Inc is a Moderate Buy with an average price target of $31.75.
See today’s analyst top recommended stocks >>
The company has a one-year high of $32.99 and a one-year low of $12.77. Currently, ACADIA Pharmaceuticals Inc has an average volume of 2.48M.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ACAD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. It operates through development and commercialization of innovative medicines segment.
Read More on ACAD:
